Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis, Growth, Shares, Size, & Trends

Irritable bowel syndrome (IBS), referred to previously as spastic or nervous colon, and spastic bowel, is a functional gastrointestinal disorder characterized by a group of symptoms accompanied together that include abdominal pain and changes in the consistency of bowel movements. These symptoms occur over a long time, often years. It has been classified into four main types depending on whether diarrhea is common, constipation is common, both are common (mixed/alternating), or neither occurs very often (IBS-D, IBS-C, IBS-M/IBS-A, or IBS-U, respectively).IBS negatively affects quality of life and may result in missed school or work. Disorders such as anxiety, major depression, and chronic fatigue syndrome are common among people with IBS. IBS does not lead to malabsorption. The only drug currently approved for IBS-D is alosetron, a 5-HT3 antagonist that may relieve abdominal pain and slow colonic and small bowel transit.

The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market will change significantly from the previous year. Over the next five years, will register a CAGR in terms of revenue, and the global market size will reach USD in millions by 2028.

Also, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market analysis report includes information on upcoming technology trends, restraints, threats, challenges and opportunities that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities. The report contains a comprehensive market and competitive landscape in addition to an analysis of the key vendors.

The Major Players in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Include:

·         Astellas Pharmaceuticals

·         Actavis

·         Pfizer

·         GlaxoSmithKline

·         Salix Pharmaceuticals Ltd

·         AstraZenenca

Market has segmented the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market on the basis of type, application, and region:

The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented by type and application. Growth between segments over the period 2022-2028 provides accurate calculations and forecasts of revenue by type and application in terms of volume and value. This analysis can help you expand your business by targeting eligible niches.

By Type:

·         Preface

·         Eluxadoline

·         Alosetron

 By Application:

·         Hospitals

·         Clinics

·         Others

 By Regional Outlook (Revenue, USD Billion, 2017 – 2028)

• North America (U.S., Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, Southeast Asia, Rest of APAC)
• Middle East & Africa (GCC Countries, South Africa, Rest of MEA)
• South America (Brazil, Argentina, Rest of South America)

IMR offers a comprehensive overview of the market through the analysis of key parameters such as revenue, price, competition, and promotions, as well as the study, synthesis, and summarization of data from different sources. It analyzes the leading industry drivers and shows numerous market components. The information offered is thorough, dependable, and the result of a comprehensive primary and secondary study. IMR market research reports offer a comprehensive global market as well as an in-depth strategic sourcing methodology and analysis based on qualitative and quantitative research to anticipate market growth.

Covid-19 Impact and Recovery Analysis on Industry:

The COVID-19 pandemic has had devastating effects on several industry verticals globally. To constrain the number of cases and slow the coronavirus spread, various public health guidelines were implemented in different countries across the globe. COVID-19 protocols ranging from declaring national emergency states, enforcing stay-at-home orders, closing nonessential business operations and schools, banning public gatherings, imposing curfews, distributing digital passes, and allowing police to restrict citizen movements within a country, as well as closing international borders. With the growing vaccination rate, governments are uplifting the protocols to give a boost to the stagnant economy. Like other industries, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market have experienced slowdown the growth, however market is expected bounce back as restrictions are being lifted up by governments across the globe. 

IMR presents a detailed study, and summation of data from multiple sources by an analysis of key parameters. Our report on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market covers the following areas:

·         Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Sizing Analysis

·         Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Forecast Analysis

·         Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Industry Analysis

Reasons to Buy

·         Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the irritable bowel syndrome (IBS) treatment market.

·         Highlights key business priorities in order to assist companies to realign their business strategies.

·         The key findings and recommendations highlight crucial progressive industry trends in the global irritable bowel syndrome (IBS) treatment market, thereby allowing players across the value chain to develop effective long-term strategies.

·         Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

·         Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

·         Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.